hepatocellular carcinoma
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Surgically resected specimens with pathologically proven HCC; 2.Aged 18 to 70 years, male or female; 3.3 weeks after hepatectomy; 4.Patients who meet one of the following risk factors: (1)Preoperative tumor diameter > 5cm; (2)Surgical margin 400 ng/ml; (6)Rupture and hemorrhage of liver cancer; 5.The ECOG 0-2; 6.Child-pugh score: A/B<=7.
Exclusion criteria
Exclusion criteria: 1.Pregnant or lactating female patients; 2.Abnormal coagulation (INR > 1.5 or PROthrombin time (PT) >4 ULN seconds), bleeding tendency or receiving thrombolysis or anticoagulant therapy; Blood coagulation is severely impaired and cannot be corrected; 3.Received molecular targeted drug therapy, radiotherapy, chemotherapy, etc., in addition to apatinib before enrollment; 4.Patients with myocardial ischemia or myocardial infarction of grade II or above, poorly controlled arrhythmias (including QTc interval male >=450 ms, female >=470 ms); 5.Patients with lung and severe renal function abnormalities; 6.Patients who are allergic to any component of Apatinib; 7.Patients with active bleeding; 8.Patients with gastrointestinal ulcer, intestinal perforation or intestinal obstruction; 9.Patients within 30 days after major surgery; 10.Patients with hypertension, whose blood pressure is still poorly controlled after antihypertensive drug therapy (systolic blood pressure > 160 mmHg, diastolic blood pressure > 100 mmHg); 11.Urine routine showed urine protein >=++ or confirmed 24 h urine protein quantity > 1.0g; 12.A history of mental illness or substance abuse.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relapse free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Drug safety; | — |
Countries
China
Contacts
The First Affiliated Hospital of Anhui Medical University